Value proposition

Fast and effective therapeutic debridement of burn injuries and chronic ulcers.

SERDA Therapeutics is a joint venture between Smith & Nephew and NLC, focused on developing innovative wound care solutions. The company is dedicated to bringing to market a proprietary, best-in-class, fast-acting therapeutic product for burn injuries and chronic ulcers.

SERDA has completed a Phase 1 Safety and Tolerability study in July 2024. This study was a blinded, randomized study that examined the immediate and 21-day cumulative irritation potential of ascending enzyme concentrations in SN514 hydrogel. The results confirm best-in-class potential for SN514 as the protection of “periwound” skin is unlikely to be necessary in clinical use.

SERDA is initiating its Phase 1b clinical study in Q4 2024 in patients with burn wounds, a major unmet clinical need in battlefield applications and natural disasters.

This clinical development program is also supported by the US Department of Defense with a grant of $2.5 million.

SERDA is raising €15 million to complete its Phase 2 clinical programs in Burn and chronic Pressure Injury

Therapeutic, Burn, Ulcer, Chronic Wound, and BioPharma